Inventor · disambiguated record
Andreas Buckl
Also filed as: BUCKL ANDREAS
13 granted patents·14 pending applications·66 citations·filing 2018–2025
89Inventor score
Files withREVOLUTION MEDICINES INC27
Top patents by PatentIndex Score
27 records- 0197US11566007B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Jan 31, 2023·10 cites·2 claims
- 0296US11739074B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Aug 29, 2023·9 cites·2 claims
- 0395US12202845B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2022·Granted Jan 21, 2025·3 cites·6 claims
- 0494US11690915B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2021·Granted Jul 4, 2023·9 cites·2 claims
- 0594US11168102B1Bicyclic heteroaryl compounds and uses thereofREVOLUTION MEDICINES INC·Filed 2020·Granted Nov 9, 2021·5 cites·18 claims
- 0694US10590090B22,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2018·Granted Mar 17, 2020·28 cites·50 claims
- 0777US11673896B2Pyridine compounds as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2019·Granted Jun 13, 2023·1 cites·16 claims
- 0876US2025074923A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 0976US2025361245A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 1075US11739093B2Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2019·Granted Aug 29, 2023·1 cites·18 claims
- 1175US2025051306A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 1275US2023374035A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
- 1373US12258366B2Bicyclic heteroaryl compounds and uses thereofREVOLUTION MEDICINES INC·Filed 2022·Granted Mar 25, 2025·0 cites·14 claims
- 1471US12365688B2Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Granted Jul 22, 2025·0 cites·36 claims
- 1570US2024067636A1Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
- 1670US2024101577A1Polycyclic compounds as allosteric shp2 inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
- 1770US2024092795A1Pyridine compounds as allosteric shp2 inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
- 1869US2025368661A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2025·Application pending·0 cites
- 1966US11702411B2Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Jul 18, 2023·0 cites·6 claims
- 2064US2021139517A1Bicyclic heteroaryl compounds and uses thereofREVOLUTION MEDICINES INC·Filed 2020·Application pending·0 cites
- 2161US11661401B22,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted May 30, 2023·0 cites·11 claims
- 2261US2025388598A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2025·Application pending·0 cites
- 2360US11673901B2Polycyclic compounds as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Jun 13, 2023·0 cites·19 claims
- 2458US2023100838A1Covalent ras inhibitors and uses thereofREVOLUTION MEDICINES INC·Filed 2022·Application pending·0 cites
- 2554US2025269037A1Compounds, complexes, and methods for their preparation and of their useREVOLUTION MEDICINES INC·Filed 2025·Application pending·0 cites
- 2648US2023096028A1Bicyclic heterocyclyl compounds and uses thereofREVOLUTION MEDICINES INC·Filed 2020·Application pending·0 cites
- 2747US2023148450A9Bicyclic heteroaryl compounds and uses thereofREVOLUTION MEDICINES INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Andreas Buckl files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →